According to the company, these patents are expected to “fuel the company’s rapid growth in the cosmetic industry” given consumer demand for products like sunscreen lotions and hair growth formulations.
Photo © Shutterstock.com/goodluz
Sabinsa Cosmetics, a division of Sabinsa Corp. (East Windsor, NJ), announced that it has received two patents for novel cosmetic compositions in the U.S. and Europe. The formulations are based on what the company says is extensive research on combinations of Sabinsa’s branded ingredients. According to the company these patents are expected to “fuel the company’s rapid growth in the cosmetic industry” given increasing consumer demand for products like sunscreen lotions and hair growth formulations.
The U.S. patent (US 9498423) is for a combination of Sabinsa’s β – glucogallin (1-O-galloyl-β-D-glucose) or β – glucogallin and total gallates from amla (Sabinsa’s branded Saberry ingredient), concentrate of liquid endosperm of Cocos nucifera (Sabinsa’s branded Cococin ingredient) and the selenopeptides (γ-L-glutamyl-Se-methyl-L-selenocysteine, and γ-L-glutamyl-L-selenomethionine) “for maintaining the morphology and numbers of the dermal papilla cells when exposed to stress signals.” Specifically, the formulation is said to protect the dermal papilla cells from stressors like UVB radiation, and maintain the number of live dermal papilla cells at a level of 95% or higher when they are exposed to UVB radiation. The company notes that this composition has also received patents in Europe (EP2695603), Japan (JP6064274), New Zealand (NZ600307) and Russia (RU2606752).
The European patent (EP2461786) is for a hair growth formulation comprising β – glucogallin (1-O-galloyl-β-D-glucose) from amla (Saberry) and a concentrate of liquid endosperm of Cocos nucifera (Cococin). In addition to promoting healthy hair growth, the company says this formulation has also been shown to protect dermal papilla cells from UV rays. The composition also previously received an Australian patent (AU2010326651).
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.